|
Patent landscape, scope, and claims: |
United States Patent US 11,806,555 (LY3009104): Claim Scope, Claim Construction Risk, and Alopecia Areata Patent Landscape
US 11,806,555 is a method-use patent that claims oral once-daily dosing of LY3009104 for alopecia areata and, in dependent form, for severe alopecia areata (patches, alopecia totalis, alopecia universalis). The enforceable core is not a molecule per se; it is a specific treatment method defined by (i) oral administration, (ii) once-daily dosing for the independent method, and (iii) therapeutic use for these clinical subtypes. The single-agent requirement is a key narrowing feature in Claim 21.
What does US 11,806,555 claim in plain terms?
Core claim set (independent methods)
- Claim 1: Treat alopecia areata by orally administering LY3009104 once daily at a therapeutically effective amount.
- Claim 11: Treat alopecia areata by orally administering LY3009104 at a therapeutically effective amount (no “once daily” limitation in the text provided).
- Claim 21: Treat severe alopecia areata by orally administering LY3009104 once daily at a therapeutically effective amount, with the explicit limitation that LY3009104 is the only therapeutically effective agent administered for treating severe alopecia areata.
Dependent claim coverage (alopecia subtype and formulation)
Across the independent claims, dependent claims specify:
- Disease phenotype
- Patches (e.g., Claims 2, 7, 12, 17, 22)
- Alopecia totalis (e.g., Claims 3, 8, 13, 18, 23)
- Alopecia universalis (e.g., Claims 4, 9, 14, 19, 24)
- Severity designation
- Severe alopecia areata (e.g., Claims 6-10, 16-20, and Claim 21 onward)
- Dosage form / composition language
- LY3009104 in a pharmaceutical composition including a pharmaceutically acceptable carrier (e.g., Claims 5, 10, 15, 20, 25)
How broad are the claims (and where are the strongest enforcement pressure points)?
1) “Method of treating” breadth
A method-of-treatment claim typically covers performance of the method steps. Here, the method steps are narrow and directly tied to:
- the patient condition (alopecia areata or severe alopecia areata),
- the route (oral),
- the agent (LY3009104),
- the dosing schedule (once daily for Claims 1 and 21),
- the therapeutic aim (treating that condition),
- and in Claim 21 only: no other therapeutically effective agent for severe disease.
2) Once-daily dosing is a major claim delimiter
- Claims 1 and 21 expressly require once daily.
- Claim 11 (as provided) lacks that once-daily language, which can matter in design-around:
- If an accused regimen is argued to be “twice daily” or otherwise not “once daily,” Claim 1 and Claim 21 become harder for the patentee to map.
- Claim 11 may still be asserted if its text is construed broadly enough to cover any oral frequency.
3) Single-agent requirement in Claim 21
Claim 21 includes an enforceability pressure point that is often decisive in combination therapy:
- “LY3009104 is the only therapeutically effective agent being administered … for treating severe alopecia areata.”
This language pushes the scope toward monotherapy and creates litigation risk for combination protocols. Even where other agents are used for supportive care, the claim hinges on whether those agents are “therapeutically effective” and “being administered … for treating severe alopecia areata.”
4) Subtype-dependent coverage
Dependent claims explicitly cover:
- patches,
- alopecia totalis,
- alopecia universalis,
each under both “alopecia areata” and “severe alopecia areata” contexts.
Practically, this reduces ambiguity in infringement arguments tied to whether the patient fits the clinical label used in an accused study.
5) “Pharmaceutical composition with carrier” dependency
Claims 5, 10, 15, 20, and 25 add a formulation limitation:
- LY3009104 in a composition with a pharmaceutically acceptable carrier.
For oral products, almost all marketed and clinical formulations include carriers/excipients, which makes this limitation less likely to be a differentiator unless the accused product uses a radically different presentation that could be argued not to include a “carrier” as construed.
Claim-by-claim scope map (what each claim is likely to cover)
| Claim |
Patient condition |
Oral administration |
Dosing schedule |
Combination limitation |
Subtype limitation |
Composition/carrier |
| 1 |
Alopecia areata |
Yes |
Once daily |
Not stated |
None |
Not stated |
| 2 |
Alopecia areata |
Yes |
Once daily |
Not stated |
Patches |
Not stated |
| 3 |
Alopecia areata |
Yes |
Once daily |
Not stated |
Alopecia totalis |
Not stated |
| 4 |
Alopecia areata |
Yes |
Once daily |
Not stated |
Alopecia universalis |
Not stated |
| 5 |
Alopecia areata |
Yes |
Once daily |
Not stated |
None |
Carrier included |
| 6 |
Severe alopecia areata |
Yes |
Once daily |
Not stated |
None |
Not stated |
| 7 |
Severe alopecia areata |
Yes |
Once daily |
Not stated |
Patches |
Not stated |
| 8 |
Severe alopecia areata |
Yes |
Once daily |
Not stated |
Alopecia totalis |
Not stated |
| 9 |
Severe alopecia areata |
Yes |
Once daily |
Not stated |
Alopecia universalis |
Not stated |
| 10 |
Severe alopecia areata |
Yes |
Once daily |
Not stated |
None |
Carrier included |
| 11 |
Alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
None |
Not stated |
| 12 |
Alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Patches |
Not stated |
| 13 |
Alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Alopecia totalis |
Not stated |
| 14 |
Alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Alopecia universalis |
Not stated |
| 15 |
Alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
None |
Carrier included |
| 16 |
Severe alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
None |
Not stated |
| 17 |
Severe alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Patches |
Not stated |
| 18 |
Severe alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Alopecia totalis |
Not stated |
| 19 |
Severe alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
Alopecia universalis |
Not stated |
| 20 |
Severe alopecia areata |
Yes |
No “once daily” text in provided claim |
Not stated |
None |
Carrier included |
| 21 |
Severe alopecia areata |
Yes |
Once daily |
Yes: only therapeutically effective agent |
None |
Not stated |
| 22 |
Severe alopecia areata |
Yes |
Once daily |
Only agent |
Patches |
Not stated |
| 23 |
Severe alopecia areata |
Yes |
Once daily |
Only agent |
Alopecia totalis |
Not stated |
| 24 |
Severe alopecia areata |
Yes |
Once daily |
Only agent |
Alopecia universalis |
Not stated |
| 25 |
Severe alopecia areata |
Yes |
Once daily |
Only agent |
None |
Carrier included |
What are the most important infringement and design-around vectors?
Vector A: dosing frequency
- Risk to once-daily competitors: Claims 1 and 21 map to once-daily oral regimens.
- Potential design-around (limited): Claim 11’s omission of “once daily” (as provided) means frequency-based design-around may not eliminate exposure for the non-severe and severe methods that align with Claim 11 and its dependent claims.
Vector B: combination therapy vs monotherapy (Claim 21)
- Highest leverage point: The “only therapeutically effective agent” clause.
- If an accused regimen adds another disease-treating agent and that agent is argued to be therapeutically effective for severe alopecia areata, Claim 21 is less likely to be infringed.
- If additional agents are supportive (and not therapeutically effective for the severe alopecia areata indication), patentee arguments can remain viable depending on evidence and how “therapeutically effective” is construed.
Vector C: oral route
- These claims are route-locked to oral administration.
- Non-oral routes (e.g., topical, injection) can fall outside literal scope, but the overall patent landscape for LY3009104 may include other claims not provided here.
Vector D: the “severe” label
- The “severe alopecia areata” dependent coverage and Claim 21 create a clinical-severity boundary.
- If a regimen is studied or marketed for non-severe alopecia areata only, severe claims may be harder to target depending on patient selection and label language.
How does the claim drafting shape enforceability (legal construction pressure points)?
“Therapeutically effective amount”
This is a functional limitation tied to treatment of the condition. In practice, it invites:
- comparison to clinical dosing ranges used in trials,
- expert analysis of whether the administered amount is within therapeutic parameters.
“Only therapeutically effective agent”
This phrase:
- is narrower than “no other drugs,”
- but it is still broad enough to raise disputes over what counts as disease-directed therapy.
Common points in litigation tend to be:
- the intent and timing of the additional agent relative to alopecia areata,
- endpoints showing therapeutic benefit attributable to other therapies,
- and whether those benefits are “for treating severe alopecia areata.”
“Once daily”
The claim requires compliance with that frequency. If an accused regimen includes long intervals and one dose per day, it still tracks. If a regimen is off-cycle or variable, the patentee will anchor to evidence of actual dosing frequency and pharmacy records.
Patent landscape: what this patent most likely covers relative to other alopecia areata/IP layers
Because only the claim text is provided and no prosecution/history, priority dates, or related patent family members are included here, the landscape assessment below is strictly structural: where this patent fits in a typical biologics/small molecule alopecia areata stack.
Where US 11,806,555 sits in a typical stack
| Layer |
What it covers |
Relevance to this patent |
| Compound/molecule patents |
LY3009104 itself (composition of matter) |
Not claimed here by the provided text; this patent is method-of-treatment |
| Formulation/product patents |
Oral drug product, excipients, capsule/tablet composition |
This patent only uses “carrier” as a dependent limitation |
| Treatment-method patents |
Indication and dosing regimen |
This is the dominant layer for enforcement |
| Clinical regimen or dosing patents |
Frequency, timing, titration |
Claims 1 and 21 embed dosing frequency and, for Claim 21, monotherapy |
Landscape implications for strategy
- Monotherapy severe disease is where claim 21 is most constraining. Any label or study protocol for severe alopecia areata with LY3009104 alone is the most directly exposed scenario.
- Once-daily oral dosing for alopecia areata is directly exposed via Claim 1 and indirectly via the related independent/severe claims depending on how “once daily” is interpreted for Claim 11’s scope.
- Combination programs for severe disease should be assessed for how “therapeutically effective” is documented for the co-administered agent.
Business impact: what claim scope means for competing development programs
If a company develops a new oral LY3009104 regimen
- Once-daily oral administration for alopecia areata and severe alopecia areata is within the method claims.
- If the program targets severe alopecia areata specifically, monotherapy designs are the highest infringement risk due to Claim 21’s only-agent limitation.
If a company uses LY3009104 in combination
- The combination could avoid Claim 21 if the additional agent is therapeutically effective for severe alopecia areata.
- Exposure to Claims 1 and 11 for alopecia areata persists because those independent claims, as provided, do not include the “only therapeutically effective agent” limitation.
If a company targets non-severe alopecia areata
- Claim 1 and Claim 11 can still attach if treatment uses oral LY3009104 and dosing maps (once-daily for Claim 1).
Key Takeaways
- US 11,806,555 is a method-of-treatment patent centered on oral LY3009104 for alopecia areata and severe alopecia areata.
- The enforceable core is defined by patient indication, oral route, and once-daily dosing in Claims 1 and 21.
- The highest leverage constraint is Claim 21’s monotherapy requirement: LY3009104 is “the only therapeutically effective agent” for treating severe alopecia areata.
- Dependent claims lock in clinical subtypes: patches, alopecia totalis, and alopecia universalis, plus dependent “carrier” language.
- For landscape strategy, infringement risk is highest for once-daily oral monotherapy in severe patients; combination programs face a specific risk gating through the “therapeutically effective” standard.
FAQs
1) Is US 11,806,555 about the LY3009104 molecule or the treatment method?
It is a method of treating claim set using LY3009104, with route and dosing limitations, not a molecule composition claim based on the provided text.
2) Which claims explicitly require once-daily dosing?
Claims 1 and 21 require once daily. Claims 11 and its severe-dependent counterparts (as provided) do not include the once-daily language.
3) Does the patent cover all alopecia areata or only specific forms?
The independent claims cover alopecia areata generally, and dependent claims specify subtypes (patches, alopecia totalis, alopecia universalis). Severe disease is separately covered via severe-dependent claims.
4) What is the main design-around lever for severe alopecia areata?
Avoiding Claim 21’s scope by using another therapeutically effective agent for severe alopecia areata (since Claim 21 requires LY3009104 as the only therapeutically effective agent).
5) Does the patent require a specific formulation beyond “carrier”?
The provided dependent claims only add that LY3009104 is in a pharmaceutical composition with a pharmaceutically acceptable carrier.
References
- US Patent 11,806,555, claims text provided by user.
More… ↓
⤷ Start Trial
|
